Skip navigation
MedlinePlus Trusted Health Information for You U.S. National Library of MedicineNational Institutes of Health
Contact Us FAQs Site Map About MedlinePlus
español Home Health Topics Drug Information Medical Encyclopedia Dictionary News Directories Other Resources

Reuters Health Information

Testosterone Rises with Treatment for Ed

Printer-friendly version E-mail this page to a friend
Reuters Health

Thursday, October 14, 2004

NEW YORK (Reuters Health) - Men who use Viagra or Cialis for erectile dysfunction (ED) have increases in levels of testosterone, Italian researchers report.

"We are now demonstrating the sexual and hormonal effect of two popular oral treatments for ED," Dr. Emmanuele A. Jannini from University of L'Aquila told Reuters Health. "Both were efficacious and able to increase testosterone levels after 3 months of treatment."

Jannini team studied 74 men with erectile dysfunction and found that free and total testosterone levels rose, overall, by about 50% after treatment.

The testosterone increases were more marked in the group that took Cialis than in the Viagra group, although the drugs were equally effective in restoring sexual potency, the investigators report in the medical journal.

The frequency of full sexual intercourse was also higher with Cialis (known chemically as tadalafil), despite the use of identical numbers of pills per month, the researchers note, "strongly suggesting that the greater normalization of hormonal values in tadalafil-treated patients was due to the higher number of sexual acts."

The higher frequency of sex "can be considered as an important benefit of tadalafil and a cost-effective advantage" for couples, the investigators suggest.

"For a man in a stable couple relationship, tadalafil is to be preferred," Jannini commented.

In this setting, the drug can be taken twice a week to allow spontaneous sexual activity. "From a psycho-sexological point of view, this may help the patient to considered himself 'cured' and not simply 'treated' for the symptom," he concluded.

SOURCE: Clinical Endocrinology, September 2004.



Copyright 2003 Reuters. Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. Reuters, the Reuters Dotted Logo and the Sphere Logo are registered trademarks of the Reuters group of companies around the world.

Related News:
More News on this Date

Related MedlinePlus Pages: